Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 11/20 | 0.38 |
| ▸ | MMP2 | P08253 | 9/20 | 0.38 |
| ▸ | MMP9 | P14780 | 4/20 | 0.37 |
| ▸ | MMP1 | P03956 | 2/20 | 0.37 |
| ▸ | MMP14 | P50281 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.34 |
| ▸ | QDPR | P09417 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | USP5 | P45974 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6437561 | 0.88 | MMP3 (0.38) | MMP3MMP2MMP9MMP1MMP14 | |
| SCHEMBL6438533 | 0.88 | MMP3 (0.38) | MMP3MMP2MMP9MMP1MMP14 | |
| SCHEMBL6434289 | 0.87 | CYP3A4 (0.44) | MMP3MMP2MMP9MMP1MAPT | |
| SCHEMBL6436433 | 0.84 | MMP3 (0.35) | MMP3MMP2MMP9MMP1MMP14 | |
| SCHEMBL6437442 | 0.84 | MMP3 (0.35) | MMP3MMP2MMP9MMP1MMP14 | |
| SCHEMBL7204028 | 0.82 | MAPT (0.38) | MMP3MMP2MMP9MMP1MMP14 | |
| SCHEMBL6435679 | 0.81 | CYP3A4 (0.46) | MMP3MMP2MMP9MMP1MMP14 | |
| SCHEMBL6966717 | 0.80 | MAPT (0.36) | MMP3MMP2MMP9MMP1MMP14 | |
| SCHEMBL6966714 | 0.80 | MAPT (0.36) | MMP3MMP2MMP9MMP1MMP14 | |
| SCHEMBL6966720 | 0.80 | MAPT (0.36) | MMP3MMP2MMP9MMP1MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1181017-B1 | METALLOPROTEASE INHIBITORS | PFIZER LTD (GB) | 2003-04-16 | — | — | EP | disclosed |
| US-6511993-B1 | Substituted alpha-aminosulphonyl-acetohydroxamic acids which are inhibitors of zinc-dependent metalloprotease enzymes | PFIZER INC. | 2003-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | MMP3 28/4885MMP2 19/4885MMP9 44/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | MMP3 28/4885MMP2 19/4885MMP9 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.